Kala Pharmaceuticals, Inc.
KALA · NASDAQ
Bulios Fair Price
$0.76
40.6% upside
Current Price
$0.54
According to Bulios Fair Price, KALA is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
Kala Pharmaceuticals, Inc. (Ticker: KALA) is a biotechnology company focused on the research and development of ophthalmic drugs. The company emphasizes innovative therapeutic approaches to eye diseases through its unique nanotechnology-based approach. Kala Pharmaceuticals is developing drugs designed to provide sustained release of therapeutic agents, which may improve the efficacy and convenience for patients. The company's focus includes indications such as dry eye disease and ocular surface inflammation. With the increasing awareness of the need for treating eye conditions, Kala Pharmaceuticals is well-positioned in the market and may offer an investment opportunity for those interested in the advancements of drugs and technologies in ophthalmology.
Sector
Healthcare
Industry
Biotechnology
CEO
Avi Minkowitz
Employees
6
Headquarters
Arlington
Upcoming events
Earnings
Upcoming earnings report